Tumor microenvironment profoundly modifies functional status of macrophages: Peritoneal and tumor-associated macrophages are two very different subpopulations

Cellular Immunology

Volumn 283, Issue 1-2, 2013, Pages 51-60

  Rodríguez, Dayron ^a   Silvera, Risset ^b   Carrio, Roberto ^b,c   Nadji, Mehrdad ^c   Caso, Raul ^c   Rodríguez, Gracielena ^c   Iragavarapu Charyulu, Vijaya ^d   Torroella Kouri, Marta ^b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d FLORIDA ATLANTIC UNIVERSITY   (United States)

Author keywords

Immunosuppression; Inflammation; Peritoneal and tumor associated macrophages; Tumor microenvironment

Indexed keywords

ARGINASE; CD11B ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 23; INTERLEUKIN 6; STAT1 PROTEIN; STAT3 PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CD3+ T LYMPHOCYTE; CELL SUBPOPULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FUNCTIONAL STATUS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PERITONEUM MACROPHAGE; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; UPREGULATION;

IMMUNOSUPPRESSION; INFLAMMATION; MDSC; MYELOID DERIVED SUPPRESSOR CELL; NORMAL PERITONEAL ELICITED MACROPHAGE; NPEM; PERITONEAL AND TUMOR-ASSOCIATED MACROPHAGES; REGULATORY T CELL; TAM; TPEM; TREG; TUMOR ASSOCIATED MACROPHAGE; TUMOR MICROENVIRONMENT; TUMOR PERITONEAL ELICITED MACROPHAGE;

ANIMALS; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE ACTIVATION; MACROPHAGES; MACROPHAGES, PERITONEAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; PHAGOCYTOSIS; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR MICROENVIRONMENT;

EID: 84880388986     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2013.06.008     Document Type: Article

References (50)

1. Witz I.P. Yin-yang activities and vicious cycles in the tumor microenvironment. Cancer Res. 2008, 68:9-13.
2. Albini A., Sporn M.B. The tumour microenvironment as a target for chemoprevention. Nat. Rev. Cancer 2007, 7:139-147.
3. Balkwill F., Charles K.A., Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005, 7:211-217.
4. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
5. Rodriguez-Vita J., Lawrence T. The resolution of inflammation and cancer. Cytokine Growth Factor Rev. 2010, 21:61-65.
6. Meira L.B., Bugni J.M., Green S.L., Lee C.W., Pang B., Borenshtein D., Rickman B.H., Rogers A.B., Moroski-Erkul C.A., McFaline J.L., Schauer D.B., Dedon P.C., Fox J.G., Samson L.D. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J. Clin. Invest. 2008, 118:2516-2525.
7. Mantovani A., Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 2010, 22:231-237.
8. Mantovani A., Sica A., Locati M. New vistas on macrophage differentiation and activation. Eur. J. Immunol. 2007, 37:14-16.
9. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23:549-555.
10. Bingle L., Brown N.J., Lewis C.E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 2002, 196:254-265.
11. Ryder M., Ghossein R.A., Ricarte-Filho J.C., Knauf J.A., Fagin J.A. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr. Relat. Cancer 2008, 15:1069-1074.
12. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 2004, 4:71-78.
13. Pollard J.W. Macrophages define the invasive microenvironment in breast cancer. J. Leukoc. Biol. 2008, 84:623-630.
14. Ostrand-Rosenberg S. Immune surveillance. A balance between protumor and antitumor immunity. Curr. Opin. Genet. Dev. 2008, 18:11-18.
15. Medina D., DeOme K.B. Response of hyperplastic alveolar nodule outgrowth-line D1 to mammary tumor virus, nodule-inducing virus, and prolonged hormonal stimulation acting singly and in combination. J. Natl. Cancer Inst. 1969, 42:303-310.
16. Owen J.L., Lopez D.M., Grosso J.F., Guthrie K.M., Herbert L.M., Torroella-Kouri M., Iragavarapu-Charyulu V. The expression of CCL2 by T lymphocytes of mammary tumor bearers: Role of tumor-derived factors. Cell Immunol. 2005, 235:122-135.
17. Torroella-Kouri M., Herbert L., Perry G., Lopez D.M. Altered IL-12 Signaling Pathways Contribute to the Deficient IFN-gamma Production by T Splenocytes from Tumor-Bearing Mice. Cancer Genomics Proteomics 2004, 1:345-354.
18. Torroella-Kouri M., Ma X., Perry G., Ivanova M., Cejas P.J., Owen J.L., Iragavarapu-Charyulu V., Lopez D.M. Diminished expression of transcription factors nuclear factor kappaB and CCAAT/enhancer binding protein underlies a novel tumor evasion mechanism affecting macrophages of mammary tumor-bearing mice. Cancer Res. 2005, 65:10578-10584.
19. Boise L.H., Minn A.J., Noel P.J., June C.H., Accavitti M.A., Lindsten T., Thompson C.B. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 1995, 3:87-98.
20. Calderon C.L., Torroella-Kouri M., Dinapoli M.R., Lopez D.M. Involvement of protein kinase C and not of NF kappa B in the modulation of macrophage nitric oxide synthase by tumor-derived phosphatidyl serine. Int. J. Oncol. 2008, 32:713-721.
21. Torroella-Kouri M., Silvera R., Rodriguez D., Caso R., Shatry A., Opiela S., Ilkovitch D., Schwendener R.A., Iragavarapu-Charyulu V., Cardentey Y., Strbo N., Lopez D.M. Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated. Cancer Res. 2009, 69:4800-4809.
22. Caso R., Silvera R., Carrio R., Iragavarapu-Charyulu V., Gonzalez-Perez R.R., Torroella-Kouri M. Blood monocytes from mammary tumor-bearing mice. early targets of tumor-induced immune suppression?. Int. J. Oncol. 2010, 37:891-900.
23. Langowski J.L., Zhang X., Wu L., Mattson J.D., Chen T., Smith K., Basham B., McClanahan T., Kastelein R.A., Oft M. IL-23 promotes tumour incidence and growth. Nature 2006, 442:461-465.
24. Huang W.L., Yeh H.H., Lin C.C., Lai W.W., Chang J.Y., Chang W.T., Su W.C. Signal transducer and activator of transcription 3 activation up-regulates interleukin-6 autocrine production: a biochemical and genetic study of established cancer cell lines and clinical isolated human cancer cells. Mol. Cancer 2010, 9:309.
25. Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 2006, 25:409-416.
26. Portielje J.E., Gratama J.W., van Ojik H.H., Stoter G., Kruit W.H. IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol. Immunother. 2003, 52:133-144.
27. Kusmartsev S., Gabrilovich D.I. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol. Immunother. 2006, 55:237-245.
28. Rodriguez P.C., Ernstoff M.S., Hernandez C., Atkins M., Zabaleta J., Sierra R., Ochoa A.C. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009, 69:1553-1560.
29. Liu Z., Li L., Yang Z., Luo W., Li X., Yang H., Yao K., Wu B., Fang W. Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer 2010, 10:270.
30. Torroella-Kouri M., Lopez D.M. Mammary tumor derived TGFb- 1 impairs crucial innate immune response in tumor hosts. J. Immunol. Immunopathol. 2003, 5:31-38.
31. Tsan M.F., Gao B. Endogenous ligands of Toll-like receptors. J. Leukoc. Biol. 2004, 76:514-519.
32. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 2010, 11:889-896.
33. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
34. Movahedi K., Laoui D., Gysemans C., Baeten M., Stange G., Van den Bossche J., Mack M., Pipeleers D., In't Veld P., De Baetselier P., Van Ginderachter J.A. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010, 70:5728-5739.
35. Sica A., Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 2007, 117:1155-1166.
36. Biswas S.K., Sica A., Lewis C.E. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J. Immunol. 2008, 180:2011-2017.
37. Lewis C.E., Pollard J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006, 66:605-612.
38. Pettersen J.S., Fuentes-Duculan J., Suarez-Farinas M., Pierson K.C., Pitts-Kiefer A., Fan L., Belkin D.A., Wang C.Q., Bhuvanendran S., Johnson-Huang L.M., Bluth M.J., Krueger J.G., Lowes M.A., Carucci J.A. Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated. J. Invest. Dermatol. 2011, 131:1322-1330.
39. Torroella-Kouri M., Keith J.C., Ivanova M., Lopez D.M. IL-11-induced reduction of C/EBP transcription factor binding may contribute to the IL-12 downregulation in tumor-bearing mice. Int. J. Oncol. 2003, 22:439-448.
40. Saccani A., Schioppa T., Porta C., Biswas S.K., Nebuloni M., Vago L., Bottazzi B., Colombo M.P., Mantovani A., Sica A. P50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. 2006, 66:11432-11440.
41. Maeda S., Kamata H., Luo J.L., Leffert H., Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005, 121:977-990.
42. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.W., Egan L.J., Kagnoff M.F., Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118:285-296.
43. Mancino A., Lawrence T. Nuclear factor-kappaB and tumor-associated macrophages. Clin. Cancer Res. 2010, 16:784-789.
44. Kusmartsev S., Gabrilovich D.I. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J. Immunol. 2005, 174:4880-4891.
45. Biswas S.K., Gangi L., Paul S., Schioppa T., Saccani A., Sironi M., Bottazzi B., Doni A., Vincenzo B., Pasqualini F., Vago L., Nebuloni M., Mantovani A., Sica A. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 2006, 107:2112-2122.
46. Kortylewski M., Xin H., Kujawski M., Lee H., Liu Y., Harris T., Drake C., Pardoll D., Yu H. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009, 15:114-123.
47. Wang L., Yi T., Kortylewski M., Pardoll D.M., Zeng D., Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 2009, 206:1457-1464.
48. Zhang J.P., Yan J., Xu J., Pang X.H., Chen M.S., Li L., Wu C., Li S.P., Zheng L. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J. Hepatol. 2009, 50:980-989.
49. Mougiakakos D., Choudhury A., Lladser A., Kiessling R., Johansson C.C. Regulatory T cells in cancer. Adv. Cancer Res. 2010, 107:57-117.
50. Blatner N.R., Bonertz A., Beckhove P., Cheon E.C., Krantz S.B., Strouch M., Weitz J., Koch M., Halverson A.L., Bentrem D.J., Khazaie K. In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proc. Natl. Acad. Sci. USA 2010, 107:6430-6435.